Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440232 | 0.79 | LMNA (0.37) | LMNAKDM4EALDH1A1GLAGAA | |
| SCHEMBL17440276 | 0.77 | LMNA (0.35) | LMNAKDM4EALDH1A1GLAGAA | |
| SCHEMBL28935727 | 0.76 | KDM4E (0.38) | LMNAKDM4EALDH1A1GLAGAA | |
| SCHEMBL5743135 | 0.76 | LMNA (0.34) | LMNAKDM4EALDH1A1GLAGAA | |
| SCHEMBL1703670 | 0.71 | PKM (0.45) | LMNAHPGDRAB9A | |
| SCHEMBL4410432 | 0.71 | LMNA (0.31) | LMNAKDM4EALDH1A1GLAGAA | |
| SCHEMBL1703757 | 0.70 | HPGD (0.48) | LMNAKDM4EALDH1A1GAAHPGD | |
| SCHEMBL2432062 | 0.70 | FSCN1 (0.39) | KDM4EALDH1A1GAAMAPK1L3MBTL1 | |
| SCHEMBL1704450 | 0.69 | PKM (0.49) | LMNAKDM4EALDH1A1GAARAB9A | |
| SCHEMBL29048373 | 0.68 | DAO (0.39) | LMNAALDH1A1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611895-A | Arylamino derivative estrogen receptor modulators and uses thereof | 四川海思科制药有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20110105564-A1 | THIENYLPYRIDYLCARBOXAMIDES | BAYER CROPSCIENCE AG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-1965640-A2 | THIENYLPYRIDYL CARBOXAMIDES | Bayer CropScience AG (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068374-A2 | THIENYLPYRIDYL CARBOXAMIDES | BAYER CROPSCIENCE AG (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105564-A1 | THIENYLPYRIDYLCARBOXAMIDES | TPI1, PGLS, TYMS | LMNA 4290/4885KDM4E 1321/4885ALDH1A1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.